Welcome to Nature’s Bioceuticals Online Store


Nature’s Bioceuticals Appoints Dr. Donald Newman To The Board Of Directors

Cape Coral, FL- November 9, 2011    
 
Nature’s Bioceuticals, a wholly owned subsidiary of Mistral Ventures Inc. (MILV.pk - News) is please to announce the appointment Dr. Donald Newman to the Board of Directors.
 
Dr. Newman owns and operates a successful holistic dental practice, Tower Dental, in Boca Raton Florida. He is an active member of The South Palm Beach Dental Society, American Dental Holistic Society, and The Gerson Institute, a non-profit organization located in San Diego, California, dedicated to the alternative, non-toxic treatment of cancer and other diseases. The Gerson Therapy is a safe, natural treatment developed by Dr. Max Gerson in the 1920’s that uses a variety of organic foods, detoxification and natural supplements to activate the body’s ability to heal itself.  Over the past 60 years, thousands of people have used the Gerson Therapy to recover from so-called “incurable” diseases such as cancer, diabetes, heart disease and arthritis.
 
Dr. Newman has a strong working knowledge of herbs and various alternative treatments. Dr. Newman is currently conducting research on the relationship between energized minerals in vegetables and their health benefits. He is also an advocate of global water quality issues as it relates to overall health and is studying alternative purification methods and ionic enhancement of waters.
 
Dr. Newman attended and graduated from Adelphi University 1969--1973 BA, Baltimore School of Dental Medicine 1974--1978 DDS and was a Captain in the United States Air Force 1978--1981.
 
Robert deZanger, CEO of Natures Bioceuticals stated “We welcome Dr. Newman as an addition to our Board. His working knowledge of natural supplements as they relate to the treatment of health problems is a perfect fit for our company. Also, we feel that the outcome of some of his research may bring additional value to the company in the future”
 
About Nature’s Bioceuticals: Nature’s Bioceuticals develops and acquires the rights to natural medicine formulas that are geared towards treating specific medical conditions. These medicines are all natural and derived from botanicals and mineral bases. Nature’s Bioceuticals strives to provide high quality natural medicines that are as effective, if not more effective, than synthetic drugs and more importantly do not have the negative side effects usually associated with many of today’s prescribed drugs.
 
Nature’s line of natural medicines will be either sold as prescription drugs, if applied for by the company and approved by the FDA, or sold as dietary supplements under the Dietary Supplement Health and Education Act of 1994, commonly referred to as "DSHEA"
 
In addition to historical information, this release contains forward-looking statements. Mistral Ventures, Inc. and/or Nature’s Bioceuticals may, from time to time, make written or oral forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements encompass Mistral Ventures, Inc. and/or Nature’s Bioceuticals beliefs, expectations, hopes, or intentions regarding future events. Words such as “expects,” “intends,” “believes,” “anticipates,” “should,” “likely,” and similar expressions identify forward-looking statements. All forward-looking statements included in this release are made as of the date hereof and are based on information available to the Company as of such date. Neither Mistral Ventures, Inc. nor Nature’s Bioceuticals assume any obligation to update any forward-looking statement. Actual results will vary, and may vary materially, from those anticipated, estimated, projected or expected for a number of reasons, including, among others: further reviews of the Company’s financial statements by the Company and its Audit Committee; modification of the Company’s accounting practices; foreign business risks; industry cyclicality; fluctuations in customer demand and order pattern; changes in pricing and general economic conditions; as well as other risks that may be delineated from time to time or filed with the SEC.
 
Media Contact: Financial Insights
Phone Number: 888 656 3509
E-mail: investors@naturesbioceuticals.com
www.naturesbioceuticals.com